Literature DB >> 25593464

E2F-1 overexpression inhibits human gastric cancer MGC-803 cell growth in vivo.

Wei-Yuan Wei1, Lin-Hai Yan1, Xiao-Tong Wang1, Lei Li1, Wen-Long Cao1, Xiao-Shi Zhang1, Ze-Xu Zhan1, Han Yu1, Yu-Bo Xie1, Qiang Xiao1.   

Abstract

AIM: To evaluate the influence of E2F-1 on the growth of human gastric cancer (GC) cells in vivo and the mechanism involved.
METHODS: E2F-1 recombinant lentiviral vectors were injected into xenograft tumors of MGC-803 cells in nude mice, and then tumor growth was investigated. Overexpression of transcription factor E2F-1 was assessed by reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting analysis. Apoptosis rates were determined using a terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) assay. Expression levels of certain cell cycle regulators and apoptosis-related proteins, such as Bax, survivin, Bcl-2, cyclin D1, S-phase kinase-associated protein 2, and c-Myc were examined by Western blotting and RT-PCR.
RESULTS: Xenograft tumors of MGC-803 cells in nude mice injected with E2F-1 recombinant lentiviral vectors stably overexpressed the E2F-1 gene as measured by semi-quantitative RT-PCR (relative mRNA expression: 0.10 ± 0.02 vs 0.05 ± 0.02 for control vector and 0.06 ± 0.03 for no infection; both P < 0.01) and Western blotting (relative protein expression: 1.90 ± 0.05 vs 1.10 ± 0.03 in control vector infected and 1.11 ± 0.02 for no infection; both P < 0.01). The growth-curve of tumor volumes revealed that infection with E2F-1 recombinant lentiviral vectors significantly inhibited the growth of human GC xenografts (2.81 ± 1.02 vs 6.18 ± 1.15 in control vector infected and 5.87 ± 1.23 with no infection; both P < 0.05) at 15 d after treatment. TUNEL analysis demonstrated that E2F-1 overexpression promoted tumor cell apoptosis (18.6% ± 2.3% vs 6.7% ± 1.2% in control vector infected 6.3% ± 1.2% for no infection; both P < 0.05). Furthermore, lentiviral vector-mediated E2F-1 overexpression increased the expression of Bax and suppressed survivin, Bcl-2, cyclin D1, Skp2, and c-Myc expression in tumor tissue.
CONCLUSION: E2F-1 inhibits growth of GC cells via regulating multiple signaling pathways, and may play an important role in targeted therapy for GC.

Entities:  

Keywords:  E2F-1; Gastric cancer; Lentiviral vector; Mouse model

Mesh:

Substances:

Year:  2015        PMID: 25593464      PMCID: PMC4292280          DOI: 10.3748/wjg.v21.i2.491

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  55 in total

1.  Expression of E2F-1 and E2F-4 is reduced in primary and metastatic breast carcinomas.

Authors:  G H Ho; J E Calvano; M Bisogna; K J Van Zee
Journal:  Breast Cancer Res Treat       Date:  2001-09       Impact factor: 4.872

2.  Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked.

Authors:  J Yang; X Liu; K Bhalla; C N Kim; A M Ibrado; J Cai; T I Peng; D P Jones; X Wang
Journal:  Science       Date:  1997-02-21       Impact factor: 47.728

3.  Inhibition of proliferation and induction of G1-phase cell-cycle arrest by dFMGEN, a novel genistein derivative, in lung carcinoma A549 cells.

Authors:  Bo Peng; Jianguo Cao; Sisi Yi; Chengkun Wang; Guopei Zheng; Zhimin He
Journal:  Drug Chem Toxicol       Date:  2012-08-30       Impact factor: 3.356

4.  Survivin siRNA inhibits gastric cancer in nude mice.

Authors:  Zhao Wenying; Ji Zhaoning; Yang Zhimin; Chen Dongyun; Sheng Lili
Journal:  Cell Biochem Biophys       Date:  2012-03       Impact factor: 2.194

5.  Adenovirus-mediated E2F-1 gene transfer efficiently induces apoptosis in melanoma cells.

Authors:  Y B Dong; H L Yang; M J Elliott; T J Liu; A Stilwell; C Atienza; K M McMasters
Journal:  Cancer       Date:  1999-11-15       Impact factor: 6.860

6.  E2F1 is crucial for E2F-dependent apoptosis.

Authors:  Eros Lazzerini Denchi; Kristian Helin
Journal:  EMBO Rep       Date:  2005-07       Impact factor: 8.807

7.  COX-2 correlates with F-box protein, Skp2 expression and prognosis in human gastric carcinoma.

Authors:  Soichiro Honjo; Satoru Kase; Mitsuhiko Osaki; Tonang Dwi Ardyanto; Nobuaki Kaibara; Hisao Ito
Journal:  Int J Oncol       Date:  2005-02       Impact factor: 5.650

Review 8.  Minireview: Cyclin D1: normal and abnormal functions.

Authors:  Maofu Fu; Chenguang Wang; Zhiping Li; Toshiyuki Sakamaki; Richard G Pestell
Journal:  Endocrinology       Date:  2004-08-26       Impact factor: 4.736

9.  Significance of E2F-1 overexpression in epithelial ovarian cancer.

Authors:  D S Suh; M S Yoon; K U Choi; J Y Kim
Journal:  Int J Gynecol Cancer       Date:  2007-08-10       Impact factor: 3.437

10.  Highly efficient generation of transgenic sheep by lentivirus accompanying the alteration of methylation status.

Authors:  Chenxi Liu; Liqin Wang; Wenrong Li; Xuemei Zhang; Yongzhi Tian; Ning Zhang; Sangang He; Tong Chen; Juncheng Huang; Mingjun Liu
Journal:  PLoS One       Date:  2013-01-29       Impact factor: 3.240

View more
  5 in total

1.  Genetic Polymorphism of E2F1 Influences Susceptibility to Ovarian Cancer in a Chinese Population.

Authors:  Yueyuan Wu; Zhiqun You; Mindan Xu
Journal:  Contrast Media Mol Imaging       Date:  2022-06-25       Impact factor: 3.009

2.  E2F-1 targets miR-519d to regulate the expression of the ras homolog gene family member C.

Authors:  Xiu-Bo Sang; Zhi-Hong Zong; Li-Li Wang; Dan-Dan Wu; Shuo Chen; Bo-Liang Liu; Yang Zhao
Journal:  Oncotarget       Date:  2017-02-28

3.  Tiliroside as a CAXII inhibitor suppresses liver cancer development and modulates E2Fs/Caspase-3 axis.

Authors:  Rui Han; Hongxing Yang; Lingeng Lu; Lizhu Lin
Journal:  Sci Rep       Date:  2021-04-21       Impact factor: 4.379

4.  Comprehensive bioinformatics analysis of the E2F family in human clear cell renal cell carcinoma.

Authors:  Zhi-Guo Liu; Jing Su; Hao Liu; Xue-Jian Yang; Xue Yang; Ye Wei; Xin-Yao Zhu; Yong Song; Xian-Cheng Zhao; Hong-Lin Guo
Journal:  Oncol Lett       Date:  2022-08-19       Impact factor: 3.111

5.  Novel Potential Therapeutic Target for E2F1 and Prognostic Factors of E2F1/2/3/5/7/8 in Human Gastric Cancer.

Authors:  Xuhong Liu; Chunhong Hu
Journal:  Mol Ther Methods Clin Dev       Date:  2020-07-31       Impact factor: 6.698

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.